Revance Therapeutics (RVNC) Reports In-Line Q2 EPS, provides guidance

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $65.3 million versus the consensus estimate of $66.3 million.

GUIDANCE:

Revance Therapeutics sees FY2024 revenue of $280 million, versus the consensus of $278.1 million. Revance now expects 2024 GAAP operating expenses from continuing operations to be between $430 million to $460 million (down from $460 million to $490 million) and non-GAAP operating expenses from continuing operations to be at the lower end of a range of $290 million to $310 million. Revance continues to expect non-GAAP SG&A expenses from continuing operations to be between $240 million to $255 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Trump: everybody is fully aware that Iran will agree to have major weapons inspections in order to ensure "nuclear honesty" long into future
• FDA launches Operation TrialBlazer to accelerate drug research